Search
QS-21
go.drugbank.com/drugs/DB05400InvestigationalAs a vaccine additive, it is currently being evaluated in clinical trials in a variety of disease areas by Antigenics. … QS-21 is an investigational adjuvant, which is a substance added to vaccines and other immunotherapies that is designed to enhance the body’s immune response to the antigen contained within the treatment
Alglucerase
go.drugbank.com/drugs/DB00088ApprovedWithdrawnHuman Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD. … Alglucerase was first approved by the FDA in 1991;[A254816] however, it was later discontinued from the market.
PF-03187207
go.drugbank.com/drugs/DB05746InvestigationalBased on the very promising preclinical results and on the well-known activities of nitric oxide, PF-03187207 is expected to have an increased capacity to reduce high IOP. … The development of abnormally high IOP, due to blockage or malfunction of systems controlling the amount of fluid in the eye, is believed to be one of the principal causes of glaucoma.
ICX-RHY
go.drugbank.com/drugs/DB05716ExperimentalThe drug was under investigation in clinical trials in the UK for the treatment of skin erosions in recessive dystrophic epidermolysis bulllosa. … ICX-RHY is an investigational therapy comprised of cultured allogeneic fibroblasts.
Triacetin
go.drugbank.com/drugs/DB16005InvestigationalCategories: Compounds used in a research, industrial, or household settingLiposomal prostaglandin E1
go.drugbank.com/drugs/DB05391InvestigationalLiposome-encapsulated form of prostaglandin E1 (Liprostin) is known to be a potent vasodilator and platelet inhibitor as well as an anti-inflammatory and anti-thrombotic agent. … The liposomal formulation of PGE-1 changes the drug’s dynamics and improve its therapeutic index in ways that PGE-1 alone could not achieve.
Synonyms: Liposomal prostaglandin E1Vimseltinib
go.drugbank.com/drugs/DB17520ApprovedInvestigationalA265035] It is intended to provide a safer alternative to [pexidartinib], a previously approved CSF1R inhibitor associated with significant liver toxicity - the greater selectivity of vimseltinib results in … [L52230,A265035] Vimseltinib - under the brand name Romvimza - was approved by the FDA in February 2025 for the treatment of tenosynovial giant cell tumours for which surgical resection is not appropriate
Thiamylal
go.drugbank.com/drugs/DB01154ApprovedVet approved(From Martindale, The Extra Pharmacopoeia, 30th ed, p919)
Metamfetamine
go.drugbank.com/drugs/DB01577ApprovedIllicitInvestigationalWithdrawnIt is a scheduled drug in most countries due to its high potential for addiction and abuse.
Synonyms: d-N-methylamphetamine, (+)-(S)-N-α-dimethylphenethylamineUrofollitropin
go.drugbank.com/drugs/DB00094ApprovedVet approvedWithdrawnUrofollitropin may also be used to cause the ovary to produce several follicles, which can then be harvested for use in gamete intrafallopian transfer (GIFT) or in vitro fertilization (IVF). … Urofollitropin is typically used injected subcutaneously in combination with human chorionic gonadotropin (hCG) to induce ovulation.
Products: . - Pulver und Lösungsmittel zur Herstellung einer Injektionslösung in einer Fertigspritze, . - Pulver und Lösungsmittel zur Herstellung einer Injektionslösung in einer Fertigspritze